Dr. Chi on Response to Tazemetostat in Children With INI1-Negative Tumors
November 28th 2018Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses response to tazemetostat in children with INI1-negative tumors.
Read More
Dr. Chi on Tazemetostat in Pediatric Patients With INI1-Negative Tumors
November 17th 2018Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses the EZH2 inhibitor tazemetostat in pediatric patients with INI1-negative tumors.
Read More
Dr. Chi Discusses Tazemetostat Trial in INI1-Negative Pediatric Tumors
August 9th 2018Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses a trial of tazemetostat in pediatric patients with INI1-negative tumors.
Read More
Dr. Chi Discusses Pediatric Atypical Teratoid Rhabdoid Tumors
July 23rd 2018Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses pediatric atypical teratoid rhabdoid tumors.
Read More
Dr. Chi on Study of Tazemetostat in Children With INI1-Negative Tumors
May 4th 2018Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of Pediatrics, Harvard Medical School, discusses a phase I multicenter trial of tazemetostat in children with INI1-negative tumors.
Read More